Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. more
Time Frame | ACLX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.3% | -3.39% | 0.2% |
1-Month Return | -7.02% | -1.92% | 2.72% |
3-Month Return | 5.17% | -10.54% | 7.31% |
6-Month Return | 52.6% | -4.47% | 10.44% |
1-Year Return | 64.91% | 4.06% | 27.53% |
3-Year Return | 388.24% | 0.94% | 30.88% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 17.91M | 110.32M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":16.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 326.00K | 629.00K | 1.04M | 2.22M | 2.04M | [{"date":"2019-12-31","value":14.66,"profit":true},{"date":"2020-12-31","value":28.28,"profit":true},{"date":"2021-12-31","value":46.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.73,"profit":true}] |
Gross Profit | (326.00K) | (629.00K) | (1.04M) | (2.22M) | 110.32M | [{"date":"2019-12-31","value":-0.3,"profit":false},{"date":"2020-12-31","value":-0.57,"profit":false},{"date":"2021-12-31","value":-0.94,"profit":false},{"date":"2022-12-31","value":-2.02,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | - | - | (12.42%) | 100.00% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-12.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 17.97M | 32.10M | 65.02M | 191.26M | 200.20M | [{"date":"2019-12-31","value":8.98,"profit":true},{"date":"2020-12-31","value":16.03,"profit":true},{"date":"2021-12-31","value":32.48,"profit":true},{"date":"2022-12-31","value":95.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (17.97M) | (32.10M) | (65.02M) | (191.26M) | (89.88M) | [{"date":"2019-12-31","value":-1797400000,"profit":false},{"date":"2020-12-31","value":-3209600000,"profit":false},{"date":"2021-12-31","value":-6501800000,"profit":false},{"date":"2022-12-31","value":-19125900000,"profit":false},{"date":"2023-12-31","value":-8988000000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | 98.00K | 5.16M | 35.25M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.28,"profit":true},{"date":"2022-12-31","value":14.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (17.97M) | (32.09M) | (64.97M) | (188.68M) | (70.03M) | [{"date":"2019-12-31","value":-1797200000,"profit":false},{"date":"2020-12-31","value":-3209500000,"profit":false},{"date":"2021-12-31","value":-6496900000,"profit":false},{"date":"2022-12-31","value":-18867900000,"profit":false},{"date":"2023-12-31","value":-7002700000,"profit":false}] |
Income Taxes | (2.00K) | 422.70K | (1.04M) | (2.58M) | 663.00K | [{"date":"2019-12-31","value":-0.3,"profit":false},{"date":"2020-12-31","value":63.76,"profit":true},{"date":"2021-12-31","value":-157.01,"profit":false},{"date":"2022-12-31","value":-389.14,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | - | (63.93M) | (186.10M) | (70.69M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-6392800000,"profit":false},{"date":"2022-12-31","value":-18609900000,"profit":false},{"date":"2023-12-31","value":-7069000000,"profit":false}] |
Income From Continuous Operations | (17.97M) | (32.09M) | (64.97M) | (188.68M) | (129.53M) | [{"date":"2019-12-31","value":-1797200000,"profit":false},{"date":"2020-12-31","value":-3209500000,"profit":false},{"date":"2021-12-31","value":-6496900000,"profit":false},{"date":"2022-12-31","value":-18867900000,"profit":false},{"date":"2023-12-31","value":-12952600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (17.97M) | (32.09M) | (63.93M) | (186.10M) | (70.69M) | [{"date":"2019-12-31","value":-1797200000,"profit":false},{"date":"2020-12-31","value":-3209500000,"profit":false},{"date":"2021-12-31","value":-6392800000,"profit":false},{"date":"2022-12-31","value":-18609900000,"profit":false},{"date":"2023-12-31","value":-7069000000,"profit":false}] |
EPS (Diluted) | - | - | (39.85) | (5.32) | (1.47) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3985,"profit":false},{"date":"2022-12-31","value":-532,"profit":false},{"date":"2023-12-31","value":-147,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ACLX | |
---|---|
Cash Ratio | 4.19 |
Current Ratio | 4.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ACLX | |
---|---|
ROA (LTM) | -6.29% |
ROE (LTM) | -10.79% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ACLX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.37 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.63 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ACLX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 28.47 |
P/B | 9.18 |
Price/FCF | 156 |
EV/R | 25.20 |
EV/Ebitda | NM |
Arcellx Inc (ACLX) share price today is $77.535
Yes, Indians can buy shares of Arcellx Inc (ACLX) on Vested. To buy Arcellx Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACLX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Arcellx Inc (ACLX) via the Vested app. You can start investing in Arcellx Inc (ACLX) with a minimum investment of $1.
You can invest in shares of Arcellx Inc (ACLX) via Vested in three simple steps:
The 52-week high price of Arcellx Inc (ACLX) is $107.37. The 52-week low price of Arcellx Inc (ACLX) is $47.88.
The price-to-earnings (P/E) ratio of Arcellx Inc (ACLX) is
The price-to-book (P/B) ratio of Arcellx Inc (ACLX) is 9.18
The dividend yield of Arcellx Inc (ACLX) is 0.00%
The market capitalization of Arcellx Inc (ACLX) is $4.44B
The stock symbol (or ticker) of Arcellx Inc is ACLX